Merck completes Cidara Therapeutics (CDTX) merger; director options cashed
Rhea-AI Filing Summary
Cidara Therapeutics director reports option cancellation tied to Merck buyout. On January 7, 2026, a Merck subsidiary completed a tender offer for all outstanding Cidara common and Series A preferred shares and then merged into Cidara, which continues as a wholly owned Merck subsidiary. In connection with the merger, each outstanding stock option became fully vested and, if unexercised, was cancelled at the merger’s effective time and converted into a cash right equal to the number of underlying shares multiplied by the excess of $221.50 per share over the option’s exercise price.
The Form 4 reports that director Joshua Resnick had stock options covering 22,200 and 5,079 Cidara common shares, both reported as derivative dispositions leaving zero options outstanding. The filing notes these options are held for the benefit of RA Capital Healthcare Fund, and Resnick is required to turn over any net cash or stock to RA Capital Management, so he disclaims beneficial ownership of the options and underlying shares.
Positive
- None.
Negative
- None.
Insights
Merger triggers cash-out of director-held options with RA Capital structure.
The disclosure shows how Cidara’s merger with Merck affected equity awards. Upon closing on January 7, 2026, all outstanding options became fully vested and were cancelled in exchange for cash equal to the number of shares per grant times the spread between $221.50 and the option exercise price. This is a standard cash-out mechanism in an all-cash acquisition.
For director Joshua Resnick, options over 22,200 and 5,079 shares were reported as derivative dispositions, leaving no options outstanding after the merger. However, footnotes explain he holds these options for the benefit of RA Capital Healthcare Fund, L.P., with any net cash or stock applied against advisory fees owed to RA Capital Management, L.P., and he disclaims beneficial ownership. This indicates the economic interest resides with the fund structure rather than the individual, and the transactions primarily reflect completion of the agreed merger terms rather than discretionary insider trading.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 22,200 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 5,079 | $0.00 | -- |
Footnotes (1)
- Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
